Related Experiment Video
Updated: Jan 10, 2026

10:03
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
2.2K
Data Augmentation via Digital Twins to Develop Personalized Deep Learning Glucose Prediction Algorithms for Type 1
IEEE Transactions on Bio-Medical Engineering
|November 21, 2025
Summary
Digital twins for type 1 diabetes (T1D) generate synthetic data, improving glucose prediction models. This approach overcomes data scarcity, enabling accurate T1D management with less patient effort.
Area of Science:
- Biomedical Engineering
- Artificial Intelligence in Healthcare
- Endocrinology
Background:
- Type 1 diabetes (T1D) management requires accurate glucose level prediction.
- Deep learning models show promise but need extensive, varied datasets.
- Collecting comprehensive T1D datasets is challenging and resource-intensive.
Purpose of the Study:
- To propose a data augmentation strategy using digital twins for T1D (DT-T1D).
- To generate personalized synthetic data for improved glucose prediction.
- To overcome limitations of data scarcity in training deep learning models.
Main Methods:
- Adapted ReplayBG, an open-source tool, to create DT-T1D from retrospective patient data.
- Developed a two-step strategy: generating DT-T1D and simulating patient-specific synthetic data.
- Trained personalized deep networks for glucose prediction using original and synthetic data.
Main Results:
- Integrating synthetic data consistently improved model performance.
- Models trained with synthetic data and a small fraction of original data matched full dataset performance.
- Demonstrated enhanced accuracy in glucose level prediction.
Conclusions:
- DT-T1D-driven data augmentation effectively addresses data scarcity in T1D research.
- This approach enhances deep learning model performance for precise glucose prediction.
- Highlights the potential of digital twin technology for robust, personalized T1D management tools.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Insulin: Dosing Regimen and Adverse Effects
663
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
663

